1. Tandem mass tag-based quantitative proteomic analysis of metformin's inhibitory effects on ovarian cancer cells
- Author
-
Wang, Dongyue, Wang, Jingchen, and Cui, Yingying
- Subjects
Drug therapy ,Analysis ,Development and progression ,Methods ,Metformin -- Analysis ,Proteomics -- Methods ,Ovarian cancer -- Development and progression -- Drug therapy - Abstract
Author(s): Dongyue Wang [1]; Jingchen Wang [2]; Yingying Cui (corresponding author) [2] INTRODUCTION Among the three major gynecological malignancies, ovarian cancer has the highest mortality rate, posing a serious threat [...], Purpose: Metformin (MET), a type 2 diabetes treatment, has attracted increased attention for its potential antitumor properties; however, the precise mechanism underlying this activity remains unclear. Our previous in vivo and in vitro studies revealed MET's inhibitory effect on ovarian cancer, with the synergistic effects of MET and the MDM2 inhibitor RG7388 contributing to ovarian cancer treatment. This study further explores the mechanism underlying MET's inhibition of ovarian cancer. Materials and Methods: Following MET treatment, we analyzed the differentially expressed proteins in ovarian cancer cells using a tandem mass tag (TMT)-based proteomic approach coupled with bioinformatics. Results: Using A2780 and SKOV3 ovarian cancer cells, we identified six upregulated and two downregulated proteins after MET treatment. Bioinformatics analysis revealed that these proteins predominately affect ovarian cancer cells by regulating iron ion transport, iron ion homeostasis, and mitochondrial and ribosomal functions. Validation via western blot confirmed MET-induced elevation of hydroxybutyrate dehydrogenase type 2 (BDH2) protein expression levels in A2780 and SKOV3 cells. Conclusions: Overall, our findings suggest that combining MET with other metabolic drugs, such as iron-chelating agents and mitochondrial inhibitors, may result in synergistic antitumor effects, thereby offering novel avenues for ovarian cancer treatment development. Keywords: BDH2, metformin, ovarian cancer, quantitative proteomics
- Published
- 2024
- Full Text
- View/download PDF